(文/解红娟 编辑/张广凯） 连续两次IPO折戟让卓正医疗的上市耐心备受考验，为规避2026年底对赌协议到期的风险，这家私立医疗机 构正在紧锣密鼓推进第三次IPO闯关。 近日，卓正医疗再度向港交所递交招股书，由海通国际与浦银国际担任联席保荐人。根据弗若斯特沙利文的 资料，以2024年的收入计，卓正医疗是中国第三大私立中高端综合医疗服务机构，市场份额为2.0%。 在此之前，卓正医疗上市征程已两度遇挫。回溯上市历程，卓正医疗首次闯关始于2024年5月16日，根据港交 所"招股书递交后6个月未完成上市流程自动失效"的规则，该份招股书于当年11月16日按期失效，首次IPO宣 告折戟。2025年3月18日，卓正医疗卷土重来递交第二份招股书，但同样因未能在6个月有效期内完成流程， 于9月18日再度失效。 距离第二份招股书失效不到两个月，卓正医疗再次提交招股书。而卓正医疗之所以对冲刺IPO如此急迫，或 许与前置投资者的对赌协议约束有关。 有媒体报道，招股书明确显示，授予IPO前投资者的赎回权已于本公司首次提交IPO日期前暂停。根据日期为 2025年3月17日的股东协议，仅在本公司的IPO被撤回、拒绝或失效；或2026年12 ...

Core Insights - The core focus of the article is on Ping An Group's introduction of its "AI Super Customer Service," which aims to create a unified AI entry point for various services, enhancing user experience and accessibility in financial, medical, and elderly care sectors [1][2]. Group 1: AI Service Development - Ping An's shift from internal efficiency to consumer-facing AI products is driven by advancements in AI technology, making professional services more feasible [2][3]. - Three key trends in AI development are identified: continuous model intelligence improvement, expansion of AI capabilities into physical spaces, and the transformation of AI into collaborative partners in work and learning environments [2][3]. Group 2: AI Service Features - The "AI Service Entrance" differs from traditional app-based one-stop service platforms by providing a comprehensive "butler-like experience" that is not limited to a specific application format [4][5]. - The "Super Customer Service" integrates over 500 online and offline services, allowing for quick resolutions to user inquiries and needs, such as roadside assistance and health consultations [5][6]. Group 3: Technical Challenges and Solutions - Key challenges include digitizing all services, ensuring collaboration between AI and human experts in complex fields like finance and healthcare, and addressing compliance and safety issues [7][8]. - Solutions involve leveraging high-quality training data, continuous learning from real business interactions, and developing a robust compliance framework to ensure AI operates within defined boundaries [8][10].

Investment Rating - The report maintains a "Buy" rating for Ping An Good Doctor (1833.HK) [4][2] Core Insights - In H1 2025, the company achieved revenue of 2.502 billion RMB, representing a growth of 19.5%, with a gross margin of 33.6%, an increase of 1.4 percentage points [1] - The net profit attributable to shareholders reached 134 million RMB, a significant increase of 137%, with a net profit margin of 5.4% [1] - Adjusted net profit, excluding share-based payments and foreign exchange losses, was 165 million RMB, up 83.6%, with an adjusted net profit margin of 6.6%, an increase of 2.3 percentage points [1] - The company effectively controlled expenses, with sales expenses of 381 million RMB (up 3.9%) and a sales expense ratio of 15.2% (down 2.3 percentage points) [1] - The F-end revenue was 1.432 billion RMB, growing by 28.5%, with a paid user base of 20 million, an increase of 34.6% [1] - The B-end enterprise health revenue was 527 million RMB, up 35.2%, with over 3,500 paid service enterprises, an increase of 37.2% [1] - The elderly care service revenue reached 172 million RMB, with a gross margin of 37.6%, an increase of 20.7 percentage points [1] Financial Forecast - Revenue projections for 2025-2027 are 5.504 billion RMB, 6.276 billion RMB, and 7.074 billion RMB, with year-on-year growth rates of 14.5%, 14.0%, and 12.7% respectively [2] - Expected net profits for the same period are 263 million RMB, 360 million RMB, and 453 million RMB, with growth rates of 223.0%, 36.7%, and 25.9% respectively [2] - The report indicates a significant improvement in profitability metrics, with projected earnings per share (EPS) of 0.12 RMB in 2025, increasing to 0.21 RMB by 2027 [3]

Core Viewpoint - Ping An Good Doctor reported strong financial results for the first half of 2025, continuing the growth trend from the previous year, with significant increases in both revenue and net profit [2][5]. Financial Performance - The company achieved a revenue of 2.502 billion RMB, representing a year-on-year growth of 19.5% [2]. - The net profit attributable to shareholders was 134 million RMB, a substantial increase of 136.8% year-on-year [2]. - The gross profit margin improved to 33.6%, up by 1.4 percentage points compared to the same period last year [2]. Business Segments - The medical services segment saw a revenue increase of 20.2% to 1.278 billion RMB, driven by deeper collaboration with Ping An Group's financial services [7]. - The health services segment generated 1.052 billion RMB, growing by 7.0%, mainly due to increased income from consumer health services like physical examinations and genetic testing [7]. - The elderly care services segment experienced a remarkable revenue growth of 263.9%, reaching 172 million RMB, with a gross profit margin increase of 20.7 percentage points to 37.6% [7]. Revenue Channels - Revenue from the comprehensive financial client segment (F-end) was 1.433 billion RMB, up 28.5%, with approximately 20 million paying users, a growth of 34.6% [9]. - Revenue from the enterprise segment (B-end) reached 527 million RMB, growing by 35.2%, with over 3.6 million paying users, an increase of 39.2% [9]. AI Integration - The company launched a "7+N+1" medical AI product system and an MDT consultation assistance platform, enhancing the application of AI in healthcare and elderly care [9]. - AI-assisted consultation accuracy reached approximately 98%, and the accuracy of complex disease treatment plans was nearly 80% [10]. - The daily volume of AI consultations reached 4 million, and the cost per service for family doctors decreased by about 52% [10]. Cost Management - As the business scaled, the proportion of total expenses to revenue decreased to 30.1%, down by 6.3 percentage points year-on-year [11]. - Management expense ratio fell to 14.9%, a decrease of 3.9 percentage points, while sales and marketing expense ratio dropped to 15.2%, down by 2.3 percentage points [11]. Market Position - Ping An Good Doctor, as a leading player in the internet healthcare sector, has seen its stock price rise over 150% this year, benefiting from the AI trend [11]. - The company's current price-to-earnings ratio (TTM) stands at 198.30 times, reflecting its elevated valuation amid rising stock prices [11].

Core Viewpoint - Ping An Health Medical Technology Co., Ltd. has become a leading provider of healthcare and elderly care management services in China, focusing on the integration of financial services and healthcare, and is expected to achieve comprehensive profitability in 2024 [1][2] Group 1: Company Overview - Established in 2014, Ping An Health is the flagship of Ping An Group's healthcare and elderly care ecosystem and was listed on the Hong Kong Stock Exchange in May 2018 [1] - The company is now an indirect non-wholly owned subsidiary of Ping An Group, with its financial performance included in the group's consolidated financial statements [1] Group 2: Financial Performance - In 2024, the company is projected to achieve total revenue of 4.808 billion yuan, with a net profit of 81 million yuan and a gross margin of 31.7%, remaining stable compared to the previous year [1] - The revenue from medical services is expected to grow steadily, while the elderly care service segment is anticipated to see accelerated growth [1] - The company reported revenues of 2.42 billion yuan from financial users (F-end) and 1.43 billion yuan from corporate clients (B-end), with F-end growing by 9.6% year-on-year and B-end by 32.7% [1] Group 3: Future Outlook and AI Integration - The company is actively exploring the integration of AI in healthcare, leveraging its own research and the technological advantages of Ping An Group [2] - The deployment of the DeepSeek model is aimed at enhancing data integration and service capabilities in healthcare [2] - Revenue forecasts for 2025-2027 are projected at 5.459 billion yuan, 6.157 billion yuan, and 6.977 billion yuan, with year-on-year growth rates of 13.5%, 12.8%, and 13.3% respectively [2] - The net profit for the same period is expected to be 205 million yuan, 311 million yuan, and 417 million yuan, with significant growth rates of 152.1%, 51.4%, and 34.0% [2]

Group 1 - The core of the collaboration between Chunyu Doctor and Zhongke Wenge focuses on integrating AI technology with traditional Chinese medicine, specifically through the development of a large model that utilizes clinical data and diagnostic cases related to tongue diagnosis [2][4] - Chunyu Doctor, founded in 2011, has become a leader in China's mobile internet healthcare sector, accumulating 1.8 billion users and over 68,000 practicing physicians on its platform by March 2025 [3] - The daily consultation volume for Chunyu Doctor exceeds 390,000, with a customer satisfaction rate of 98%, indicating its effectiveness as a comprehensive digital healthcare platform [5] Group 2 - Zhongke Wenge, an AI enterprise incubated by the Chinese Academy of Sciences, focuses on decision intelligence technology and has developed proprietary systems for AI data operations and multi-modal models [6] - The strategic partnership aims to create an integrated AI service system for traditional Chinese medicine that encompasses prevention, diagnosis, treatment, and health management [4]